-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
Can this synthetic oil help feed the brain in Huntington's disease?
A new study shows a synthetic oil called triheptanoin changes how HD brains use energy. But will it help HD?
-
Positive results announced for re-worked tetrabenazine drug in Huntington's disease
Modified 'heavy hydrogen' form of tetrabenazine appears safe and effective for chorea in Huntington's disease
-
Turning skin cells into brain cells: a Huntington's disease research breakthrough?
Scientists can now change human skin cells into working neurons, like the ones that are most affected in HD.
-
Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
A clinical trial for an exciting therapy against HD is planned for 2015. The first step is to make sure it is safe.
-
Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis
CREST-E, a trial of the supplement creatine, has been stopped after an early analysis found it couldn't show benefit
-
Should we worry about a huntingtin invasion?
Cool lab experiments show the huntington's disease protein jumping between cells. Does this matter for HD patients?
-
EuroBuzz 2014 Video, day one
Video of our first live session at the European Huntington's Disease Network Meeting.
-
EuroBuzz 2014 Video, day two
Video of our second live session at the European Huntington's Disease Network Meeting.
-
Melatonin alterations in Huntington's disease help explain trouble with sleep
Study shows HD patients have decreased levels of melatonin, which may explain why so many suffer from sleep problems
-
EuroBuzz 2014: day three
Our third and final report on the 2014 European Huntington's Disease Network meeting in Barcelona
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
